pipeline-prospector-insert
X

Find Drugs for Cardiology/Vascular Diseases in Preclinical Development in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Gene-editing therapies

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: ARCH Venture Partners

            Deal Size: $63.0 million Upfront Cash: Undisclosed

            Deal Type: Series A2 Financing June 11, 2020

            Details:

            The company will use the financing to advance its lead program through IND-enabling studies and fuel follow-on pipeline programs.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AAV-Gene Therapy

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 11, 2020

            Details:

            Three posters illustrate advances made with Tenaya's Cellular Regeneration platform using direct reprogramming of resident cardiac fibroblasts to create new cardiomyocytes.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Neurokinin 1 receptor positive mesenchymal stem cell

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 05, 2020

            Details:

            Animal research findings show substantial improvements in heart function for heart failure subjects treated with BioCardia's allogeneic neurokinin 1 receptor positive mesenchymal stem cell, CardiALLOTM.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): D6PV

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 30, 2020

            Details:

            Early preclinical studies show peptide D6PV has the ability to activate the enzyme called Lipo-Protein Lipase (LPL), rapidly (within 1 -3 hours) reducing the number of triglycerides in the bloodstream